Archives

by in
Entry Author Date Location
ASH Roundup: Immunotherapy Stars, Gene Therapy Leaps Ahead 12/11/14 San Francisco
East Coast Biotech Roundup: Agios, Vertex, Epizyme, Celldex, & More 11/21/14 Boston
Boston’s Life Science Disruptors: The Photos 10/21/14 Boston
East Coast Biotech Roundup: Raze, Retrophin, Alnylam, & More 10/16/14 Boston
With $24M and Pharma Backing, Ex Epizyme Prez Aims to “Raze” Tumors 10/14/14 Boston
Six Takeaways from Boston’s Life Science Disruptors 10/13/14 Boston
One Week to Boston’s Life Science Disruptors—Check Out the Agenda 10/01/14 Boston
Well-Traveled Rhodes Leaves Epizyme For Atlas Venture Partnership 09/29/14 Boston
Hear Epizyme, Sage, Zafgen Share Their Stories on Oct. 8 09/11/14 Boston
East Coast Biotech Roundup: NJ Blues, Genzyme, Amicus, Biogen & More 08/25/14 Boston
Join Us For “Boston’s Life Science Disruptors” on Oct. 8 08/21/14 Boston
East Coast Biotech Roundup: Amicus, Accelerator, Seventh Sense, & More 08/15/14 Boston
East Coast Biotech Roundup: Mergers, Rhythm, Regeneron, & More 05/09/14 Boston
7 Takeaways From “What’s Hot in Boston Biotech” 04/22/14 Boston
East Coast Biotech Roundup: Berg, Forma/Celgene, Intarcia, & More 04/04/14 Boston
Foresite Capital Reloads With New $300M Late-Stage Biotech Fund 04/01/14 San Francisco
What’s Hot in Boston Biotech: Here’s the Agenda for April 16 03/27/14 Boston
East Coast Biotech Roundup: Dicerna, J&J, Neurophage, & More 01/31/14 Boston
Epizyme Heads Back to Wall Street, Plans $140M Raise 01/27/14 Boston
East Coast Biotech Roundup: Gerngross, Akili, Intercept, & More 01/10/14 Boston
Fresh from IPO, Five Prime Advances Arthritis and Cancer Drugs 12/19/13 San Francisco
East Coast Biotech Roundup: Juno, Editas, Celgene, & More 12/06/13 Boston
Celgene Plunks Down $177M Upfront for OncoMed’s Stem Cell Drugs 12/03/13 San Francisco
3 Life Sciences Companies That Are Built to Last 12/02/13 National
New Enterprise Associates Sets up Shop in Kendall Square 11/14/13 Boston
Xconomy Boston’s Top 10 Stories from Q3 2013: Editor’s Picks 09/30/13 Boston
Which VCs Are Poised to Profit From the Biotech IPO Boom? 09/09/13 National
Biotech and Fantasy Football Picks for Fall 2013 09/03/13 National
Syndax Pockets $26.6M For Final Stage Push With Cancer Drug 08/27/13 Boston
Who Should Biotech Pros Follow on Twitter? An Update for 2013 08/19/13 National
Page 1 of 3 next page »